{"id": "article-30555_0", "title": "Trazodone -- Continuing Education Activity", "content": "Trazodone is a medication used in the management and treatment of major depressive disorder. This drug is in the serotonin-antagonist-and-reuptake-inhibitor class of medications; it can be used as a component of combination therapy with other drugs or psychotherapies or as monotherapy for treating depression. Trazodone is\u00a0an\u00a0antidepressant\u00a0that\u00a0inhibits serotonin transporter and serotonin type 2 receptors; it\u00a0is a\u00a0triazolopyridine\u00a0derivative. Trazodone inhibits the reuptake of serotonin and blocks the histamine and \u03b1-1-adrenergic receptors.\u00a0This activity reviews the indications, actions, and contraindications for trazodone as a valuable agent in managing major depression. This activity will highlight the mechanism of actions, adverse effects, and other key factors (eg, off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions) pertinent to interprofessional team members in treating patients with depression and related conditions.", "contents": "Trazodone -- Continuing Education Activity. Trazodone is a medication used in the management and treatment of major depressive disorder. This drug is in the serotonin-antagonist-and-reuptake-inhibitor class of medications; it can be used as a component of combination therapy with other drugs or psychotherapies or as monotherapy for treating depression. Trazodone is\u00a0an\u00a0antidepressant\u00a0that\u00a0inhibits serotonin transporter and serotonin type 2 receptors; it\u00a0is a\u00a0triazolopyridine\u00a0derivative. Trazodone inhibits the reuptake of serotonin and blocks the histamine and \u03b1-1-adrenergic receptors.\u00a0This activity reviews the indications, actions, and contraindications for trazodone as a valuable agent in managing major depression. This activity will highlight the mechanism of actions, adverse effects, and other key factors (eg, off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions) pertinent to interprofessional team members in treating patients with depression and related conditions."}
{"id": "article-30555_1", "title": "Trazodone -- Continuing Education Activity", "content": "Objectives: Identify appropriate indications for trazodone therapy in psychiatric and non-psychiatric settings. Differentiate between trazodone and other antidepressants regarding efficacy, safety profile, and potential drug interactions. Implement evidence-based strategies for titrating trazodone dosage and managing side effects to optimize treatment outcomes. Collaborate with mental health specialists, pharmacists, and other interprofessional healthcare team members to optimize trazodone therapy and ensure patient safety. Access free multiple choice questions on this topic.", "contents": "Trazodone -- Continuing Education Activity. Objectives: Identify appropriate indications for trazodone therapy in psychiatric and non-psychiatric settings. Differentiate between trazodone and other antidepressants regarding efficacy, safety profile, and potential drug interactions. Implement evidence-based strategies for titrating trazodone dosage and managing side effects to optimize treatment outcomes. Collaborate with mental health specialists, pharmacists, and other interprofessional healthcare team members to optimize trazodone therapy and ensure patient safety. Access free multiple choice questions on this topic."}
{"id": "article-30555_2", "title": "Trazodone -- Indications -- FDA-Approved Indications", "content": "Trazodone is an\u00a0FDA-approved\u00a0antidepressant for treating major depressive disorders. [1] The drug can be\u00a0used as\u00a0a component of combination therapy with other drugs or psychotherapies or as monotherapy\u00a0for treating depression. [2]", "contents": "Trazodone -- Indications -- FDA-Approved Indications. Trazodone is an\u00a0FDA-approved\u00a0antidepressant for treating major depressive disorders. [1] The drug can be\u00a0used as\u00a0a component of combination therapy with other drugs or psychotherapies or as monotherapy\u00a0for treating depression. [2]"}
{"id": "article-30555_3", "title": "Trazodone -- Indications -- Non-FDA-Approved Uses", "content": "Trazodone is used\u00a0off-label for patients\u00a0with insomnia. Trazodone is not FDA-approved for sleep disorders\u00a0due to insufficient\u00a0clinical data to justify its use as a sedative agent. [3] Trazodone is also used off-label for anxiety, Alzheimer disease, substance misuse, bulimia, and fibromyalgia due to its serotonergic receptor antagonism and serotonin reuptake-inhibiting effects. [4] Trazodone has also been used for post-traumatic stress disorder (PTSD) if the first-line treatment of SSRIs does not\u00a0demonstrate efficacy. The dose of 50 to 200 mg of trazodone has been shown to reduce nightmare episodes of nightmares as well as improve sleep habits\u00a0in studies involving PTSD patients. According to the American Academy of Sleep Medicine (AASM), trazodone is suggested to treat nightmares associated with PTSD. [5] However, various studies\u00a0show patients with panic symptoms have\u00a0suffered\u00a0exacerbation in some instances, which is why SSRIs,\u00a0instead of\u00a0trazodone,\u00a0are preferred as the first-line treatment for PTSD. Additionally, research has shown trazodone\u00a0improves apnea and hypopnea\u00a0episodes in patients with obstructive sleep apnea (OSA), and the drug does not worsen hypoxemic episodes. [6] Trazodone raises the respiratory threshold, lowering the risk of respiratory instability. [7]", "contents": "Trazodone -- Indications -- Non-FDA-Approved Uses. Trazodone is used\u00a0off-label for patients\u00a0with insomnia. Trazodone is not FDA-approved for sleep disorders\u00a0due to insufficient\u00a0clinical data to justify its use as a sedative agent. [3] Trazodone is also used off-label for anxiety, Alzheimer disease, substance misuse, bulimia, and fibromyalgia due to its serotonergic receptor antagonism and serotonin reuptake-inhibiting effects. [4] Trazodone has also been used for post-traumatic stress disorder (PTSD) if the first-line treatment of SSRIs does not\u00a0demonstrate efficacy. The dose of 50 to 200 mg of trazodone has been shown to reduce nightmare episodes of nightmares as well as improve sleep habits\u00a0in studies involving PTSD patients. According to the American Academy of Sleep Medicine (AASM), trazodone is suggested to treat nightmares associated with PTSD. [5] However, various studies\u00a0show patients with panic symptoms have\u00a0suffered\u00a0exacerbation in some instances, which is why SSRIs,\u00a0instead of\u00a0trazodone,\u00a0are preferred as the first-line treatment for PTSD. Additionally, research has shown trazodone\u00a0improves apnea and hypopnea\u00a0episodes in patients with obstructive sleep apnea (OSA), and the drug does not worsen hypoxemic episodes. [6] Trazodone raises the respiratory threshold, lowering the risk of respiratory instability. [7]"}
{"id": "article-30555_4", "title": "Trazodone -- Mechanism of Action", "content": "Trazodone is\u00a0an\u00a0antidepressant\u00a0that\u00a0inhibits serotonin transporter and serotonin type 2 receptors; it\u00a0is a\u00a0triazolopyridine\u00a0derivative. Trazodone inhibits the reuptake of serotonin and blocks the histamine and \u03b1-1-adrenergic receptors.\u00a0The drug also induces significant changes in 5-HT presynaptic receptor\u00a0adrenoreceptors. The full spectrum of trazodone\u2019s mechanism\u00a0of action is not fully understood, explaining\u00a0its\u00a0off-label\u00a0uses. Trazodone is in the category of SARI drugs\u00a0(serotonin antagonist and reuptake inhibitors), with other members being\u00a0phenylpiperazine,\u00a0etoperidone,\u00a0lorpiprazole, and\u00a0mepiprazole. [8]", "contents": "Trazodone -- Mechanism of Action. Trazodone is\u00a0an\u00a0antidepressant\u00a0that\u00a0inhibits serotonin transporter and serotonin type 2 receptors; it\u00a0is a\u00a0triazolopyridine\u00a0derivative. Trazodone inhibits the reuptake of serotonin and blocks the histamine and \u03b1-1-adrenergic receptors.\u00a0The drug also induces significant changes in 5-HT presynaptic receptor\u00a0adrenoreceptors. The full spectrum of trazodone\u2019s mechanism\u00a0of action is not fully understood, explaining\u00a0its\u00a0off-label\u00a0uses. Trazodone is in the category of SARI drugs\u00a0(serotonin antagonist and reuptake inhibitors), with other members being\u00a0phenylpiperazine,\u00a0etoperidone,\u00a0lorpiprazole, and\u00a0mepiprazole. [8]"}
{"id": "article-30555_5", "title": "Trazodone -- Mechanism of Action", "content": "Clinical studies\u00a0have shown\u00a0trazodone\u00a0is comparable\u00a0in\u00a0efficacy to other drug classes, such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitors (SNRIs) in treating major depressive disorders. Also, trazodone has better tolerance than second-generation SSRIs, which are\u00a0highly associated with insomnia, anxiety, and sexual dysfunction. [9] The unique\u00a0property of\u00a0trazodone,\u00a0which simultaneously\u00a0inhibits\u00a0SERT, 5-HT2A, and 5-HT2C receptors, avoids the issue of sexual dysfunction, insomnia, and anxiety that commonly presents with SSRI and SNRI therapy.", "contents": "Trazodone -- Mechanism of Action. Clinical studies\u00a0have shown\u00a0trazodone\u00a0is comparable\u00a0in\u00a0efficacy to other drug classes, such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitors (SNRIs) in treating major depressive disorders. Also, trazodone has better tolerance than second-generation SSRIs, which are\u00a0highly associated with insomnia, anxiety, and sexual dysfunction. [9] The unique\u00a0property of\u00a0trazodone,\u00a0which simultaneously\u00a0inhibits\u00a0SERT, 5-HT2A, and 5-HT2C receptors, avoids the issue of sexual dysfunction, insomnia, and anxiety that commonly presents with SSRI and SNRI therapy."}
{"id": "article-30555_6", "title": "Trazodone -- Mechanism of Action", "content": "Trazodone reduces neurotransmitters associated with arousal effects, such as serotonin, noradrenaline, dopamine, acetylcholine, and histamine. Low-dose trazodone use exerts a sedative effect on sleep through the antagonism of the 5-HT-2A receptor, H1 receptor, and alpha-1-adrenergic receptors.\u00a0Furthermore, a recent study on human astrocytes showed\u00a0trazodone\u00a0helps decrease inflammatory mediator release and helps normalize trophic and metabolic support during inflammation of neurons, which is associated with major depression.", "contents": "Trazodone -- Mechanism of Action. Trazodone reduces neurotransmitters associated with arousal effects, such as serotonin, noradrenaline, dopamine, acetylcholine, and histamine. Low-dose trazodone use exerts a sedative effect on sleep through the antagonism of the 5-HT-2A receptor, H1 receptor, and alpha-1-adrenergic receptors.\u00a0Furthermore, a recent study on human astrocytes showed\u00a0trazodone\u00a0helps decrease inflammatory mediator release and helps normalize trophic and metabolic support during inflammation of neurons, which is associated with major depression."}
{"id": "article-30555_7", "title": "Trazodone -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Peak plasma concentrations are\u00a0approximately\u00a0achieved within 1 hour of oral administration.\u00a0The bioavailability\u00a0of trazodone is approximately 100%. [10] Distribution: Trazodone has\u00a089% to 95% plasma protein binding.", "contents": "Trazodone -- Mechanism of Action -- Pharmacokinetics. Absorption: Peak plasma concentrations are\u00a0approximately\u00a0achieved within 1 hour of oral administration.\u00a0The bioavailability\u00a0of trazodone is approximately 100%. [10] Distribution: Trazodone has\u00a089% to 95% plasma protein binding."}
{"id": "article-30555_8", "title": "Trazodone -- Mechanism of Action -- Pharmacokinetics", "content": "Metabolism: Trazodone is extensively metabolized by CYP3A4 to an active metabolite, m-chlorophenyl piperazine(m-CPP). Evidence suggests CYP2D6 plays a minor role in the metabolism of trazodone. [11] [12] Excretion: Trazodone is primarily excreted\u00a0via\u00a0urine. The terminal elimination half-life of trazodone is 5\u00a0to 9 hours. [13]", "contents": "Trazodone -- Mechanism of Action -- Pharmacokinetics. Metabolism: Trazodone is extensively metabolized by CYP3A4 to an active metabolite, m-chlorophenyl piperazine(m-CPP). Evidence suggests CYP2D6 plays a minor role in the metabolism of trazodone. [11] [12] Excretion: Trazodone is primarily excreted\u00a0via\u00a0urine. The terminal elimination half-life of trazodone is 5\u00a0to 9 hours. [13]"}
{"id": "article-30555_9", "title": "Trazodone -- Administration", "content": "Trazodone is administered via the oral route.\u00a0The medication is available in oral tablets of trazodone hydrochloride\u00a050, 100, 150, and 300 mg in the US. It may be administered after meals to decrease lightheadedness and postural hypotension.", "contents": "Trazodone -- Administration. Trazodone is administered via the oral route.\u00a0The medication is available in oral tablets of trazodone hydrochloride\u00a050, 100, 150, and 300 mg in the US. It may be administered after meals to decrease lightheadedness and postural hypotension."}
{"id": "article-30555_10", "title": "Trazodone -- Administration", "content": "Major depressive disorder: Immediate-release formulation: 50 to 100 mg orally 2 or 3 times daily. Start at 25 to 50 mg 2 or 3 times daily, and increase by 50 mg each day every 3 or 4 days to a maximum dosage of 400 mg daily for outpatients and 600 mg daily for inpatients. Dosing should be tapered to discontinue. A study examined the use of trazodone extended-release formulation following IV trazodone.\u00a0They began with\u00a0an evening administration of 75 to 150 mg before bedtime as a prolonged-release once-a-day administration. This regimen helps optimize its purpose as an antidepressant, eliciting higher compliance. [14] The dose may be increased every third day, up to 300 mg daily. The dose may be up to 600 mg per day (maximum recommended dose of trazodone) in hospitalized patients. The results of multi-drug regiment studies showed that using citalopram and fluoxetine with trazodone had no significant impact on any alteration of serum level and no increased risk of headache, sedation, or serotonin syndrome.", "contents": "Trazodone -- Administration. Major depressive disorder: Immediate-release formulation: 50 to 100 mg orally 2 or 3 times daily. Start at 25 to 50 mg 2 or 3 times daily, and increase by 50 mg each day every 3 or 4 days to a maximum dosage of 400 mg daily for outpatients and 600 mg daily for inpatients. Dosing should be tapered to discontinue. A study examined the use of trazodone extended-release formulation following IV trazodone.\u00a0They began with\u00a0an evening administration of 75 to 150 mg before bedtime as a prolonged-release once-a-day administration. This regimen helps optimize its purpose as an antidepressant, eliciting higher compliance. [14] The dose may be increased every third day, up to 300 mg daily. The dose may be up to 600 mg per day (maximum recommended dose of trazodone) in hospitalized patients. The results of multi-drug regiment studies showed that using citalopram and fluoxetine with trazodone had no significant impact on any alteration of serum level and no increased risk of headache, sedation, or serotonin syndrome."}
{"id": "article-30555_11", "title": "Trazodone -- Administration", "content": "Insomnia: Studies showed that administering 50 to 100 mg per day of trazodone helped nonorganic insomnia due to depressive disorder, with 100 mg dosage as the most effective to improve sleep. Trazodone may be available as immediate-release\u00a0(IR) tablets and, in some countries, prolonged-release tablets, oral drops, and injection solutions.\u00a0Abrupt discontinuation of trazodone can lead to\u00a0nausea, dysphoria, agitation, and sensory disturbances. Gradual tapering is recommended when discontinuing trazodone. [15]", "contents": "Trazodone -- Administration. Insomnia: Studies showed that administering 50 to 100 mg per day of trazodone helped nonorganic insomnia due to depressive disorder, with 100 mg dosage as the most effective to improve sleep. Trazodone may be available as immediate-release\u00a0(IR) tablets and, in some countries, prolonged-release tablets, oral drops, and injection solutions.\u00a0Abrupt discontinuation of trazodone can lead to\u00a0nausea, dysphoria, agitation, and sensory disturbances. Gradual tapering is recommended when discontinuing trazodone. [15]"}
{"id": "article-30555_12", "title": "Trazodone -- Administration -- Specific Patient Populations", "content": "Hepatic impairment: Trazodone use has not been studied in patients with liver impairment, and\u00a0the recommendation is to use trazodone with caution in this population. Renal impairment: Trazodone use is not studied in patients with renal impairment, and it is recommended to use trazodone cautiously\u00a0in this population. [16]", "contents": "Trazodone -- Administration -- Specific Patient Populations. Hepatic impairment: Trazodone use has not been studied in patients with liver impairment, and\u00a0the recommendation is to use trazodone with caution in this population. Renal impairment: Trazodone use is not studied in patients with renal impairment, and it is recommended to use trazodone cautiously\u00a0in this population. [16]"}
{"id": "article-30555_13", "title": "Trazodone -- Administration -- Specific Patient Populations", "content": "Pregnancy considerations: Clinicians\u00a0should register pregnant patients with depression in the National Pregnancy Registry for Antidepressants, which monitors pregnancy outcomes in patients exposed to antidepressants during pregnancy. Published literature on trazodone use in pregnant women has not found any associated risks of miscarriage, significant congenital disabilities, or adverse maternal or fetal outcomes. [17] The clinical study was conducted on 201 pregnant patients with a major depressive disorder history who became euthymic while using antidepressants at the beginning of pregnancy.\u00a0The study showed that patients who discontinued antidepressants during pregnancy have more chances of experiencing a relapse of major depression than women who continued treatment with antidepressants. Therefore, it is advisable to consider the risk of untreated depression if planning to discontinue or change antidepressant treatment while a patient is pregnant or postpartum.", "contents": "Trazodone -- Administration -- Specific Patient Populations. Pregnancy considerations: Clinicians\u00a0should register pregnant patients with depression in the National Pregnancy Registry for Antidepressants, which monitors pregnancy outcomes in patients exposed to antidepressants during pregnancy. Published literature on trazodone use in pregnant women has not found any associated risks of miscarriage, significant congenital disabilities, or adverse maternal or fetal outcomes. [17] The clinical study was conducted on 201 pregnant patients with a major depressive disorder history who became euthymic while using antidepressants at the beginning of pregnancy.\u00a0The study showed that patients who discontinued antidepressants during pregnancy have more chances of experiencing a relapse of major depression than women who continued treatment with antidepressants. Therefore, it is advisable to consider the risk of untreated depression if planning to discontinue or change antidepressant treatment while a patient is pregnant or postpartum."}
{"id": "article-30555_14", "title": "Trazodone -- Administration -- Specific Patient Populations", "content": "Breastfeeding considerations: Trazodone is excreted in human milk, and no data shows its effect on milk production. [18] Postmarketing reports\u00a0provide limited data, and\u00a0these reports have not identified an association of adverse effects of trazodone use on the breastfed child. The maternal need for trazodone should be assessed along with the risk of\u00a0development and health benefits of breastfeeding the child. According to the safety scoring system use of trazodone should be used cautiously while breastfeeding, especially for infants. [19]", "contents": "Trazodone -- Administration -- Specific Patient Populations. Breastfeeding considerations: Trazodone is excreted in human milk, and no data shows its effect on milk production. [18] Postmarketing reports\u00a0provide limited data, and\u00a0these reports have not identified an association of adverse effects of trazodone use on the breastfed child. The maternal need for trazodone should be assessed along with the risk of\u00a0development and health benefits of breastfeeding the child. According to the safety scoring system use of trazodone should be used cautiously while breastfeeding, especially for infants. [19]"}
{"id": "article-30555_15", "title": "Trazodone -- Administration -- Specific Patient Populations", "content": "Pediatric patients : FDA has issued\u00a0a boxed warning on an increased risk of suicidal thoughts and behaviors in pediatric patients with antidepressant medication use. Additionally, the efficacy and safety of trazodone in the pediatric population have not been established.", "contents": "Trazodone -- Administration -- Specific Patient Populations. Pediatric patients : FDA has issued\u00a0a boxed warning on an increased risk of suicidal thoughts and behaviors in pediatric patients with antidepressant medication use. Additionally, the efficacy and safety of trazodone in the pediatric population have not been established."}
{"id": "article-30555_16", "title": "Trazodone -- Administration -- Specific Patient Populations", "content": "Older patients: The dose for older patients should\u00a0be reduced\u00a0to 100 mg per day.\u00a0Trazodone should be used carefully in\u00a0older patients as serotonergic antidepressants are associated with hyponatremia in\u00a0these patients, who are already at greater risk for this adverse reaction. [20]", "contents": "Trazodone -- Administration -- Specific Patient Populations. Older patients: The dose for older patients should\u00a0be reduced\u00a0to 100 mg per day.\u00a0Trazodone should be used carefully in\u00a0older patients as serotonergic antidepressants are associated with hyponatremia in\u00a0these patients, who are already at greater risk for this adverse reaction. [20]"}
{"id": "article-30555_17", "title": "Trazodone -- Adverse Effects", "content": "The primary adverse effects of trazodone include headaches, fatigue, dizziness, drowsiness,\u00a0and somnolence. Other risks include anticholinergic effects (dry mouth), orthostatic hypotension, syncope, QT prolongation, Torsade de pointes, priapism, and\u00a0increased suicidal thoughts. QT prolongation and arrhythmia risks\u00a0are\u00a0due to the interaction of trazodone with\u00a0hERG\u00a0potassium channels.", "contents": "Trazodone -- Adverse Effects. The primary adverse effects of trazodone include headaches, fatigue, dizziness, drowsiness,\u00a0and somnolence. Other risks include anticholinergic effects (dry mouth), orthostatic hypotension, syncope, QT prolongation, Torsade de pointes, priapism, and\u00a0increased suicidal thoughts. QT prolongation and arrhythmia risks\u00a0are\u00a0due to the interaction of trazodone with\u00a0hERG\u00a0potassium channels."}
{"id": "article-30555_18", "title": "Trazodone -- Adverse Effects", "content": "Antidepressants are associated with an increased risk of suicidal thinking, especially in younger adults, adolescents, and children. Despite the presence of anticholinergic effects, the risk of urinary retention and constipation is less than tricyclic antidepressants, such as imipramine or amitriptyline.\u00a0The risk for orthostatic hypotension is higher in older patients, especially those\u00a0with pre-existing heart conditions, due to the adrenergic \u03b11-receptor blockade.\u00a0Patients typically show adverse effects\u00a0of somnolence and hypotension during the first week of administration.\u00a0Special care is necessary for\u00a0male patients with sickle cell anemia, multiple myeloma, leukemia,\u00a0autonomic\u00a0dysfunction,\u00a0hypercoagulable\u00a0state, or those with a penile anatomic variation such as angulation,\u00a0cavernosal\u00a0fibrosis, or\u00a0Peyronie disease, as\u00a0the drug can cause priapism in these individuals. [21]", "contents": "Trazodone -- Adverse Effects. Antidepressants are associated with an increased risk of suicidal thinking, especially in younger adults, adolescents, and children. Despite the presence of anticholinergic effects, the risk of urinary retention and constipation is less than tricyclic antidepressants, such as imipramine or amitriptyline.\u00a0The risk for orthostatic hypotension is higher in older patients, especially those\u00a0with pre-existing heart conditions, due to the adrenergic \u03b11-receptor blockade.\u00a0Patients typically show adverse effects\u00a0of somnolence and hypotension during the first week of administration.\u00a0Special care is necessary for\u00a0male patients with sickle cell anemia, multiple myeloma, leukemia,\u00a0autonomic\u00a0dysfunction,\u00a0hypercoagulable\u00a0state, or those with a penile anatomic variation such as angulation,\u00a0cavernosal\u00a0fibrosis, or\u00a0Peyronie disease, as\u00a0the drug can cause priapism in these individuals. [21]"}
{"id": "article-30555_19", "title": "Trazodone -- Adverse Effects", "content": "In some cases, trazodone use has correlated with visual hallucinations.\u00a0Hallucinations generally\u00a0resolve with the discontinuation of trazodone, and\u00a0clinicians should switch the patient to\u00a0another antidepressant medication. [22] Before initiating trazodone,\u00a0obtain a personal and family history of bipolar disorder.\u00a0Trazodone-induced\u00a0mania has been reported. [23] Bleeding risk is a potential complication associated with trazodone, although the risk is lower than with other antidepressants. [24]", "contents": "Trazodone -- Adverse Effects. In some cases, trazodone use has correlated with visual hallucinations.\u00a0Hallucinations generally\u00a0resolve with the discontinuation of trazodone, and\u00a0clinicians should switch the patient to\u00a0another antidepressant medication. [22] Before initiating trazodone,\u00a0obtain a personal and family history of bipolar disorder.\u00a0Trazodone-induced\u00a0mania has been reported. [23] Bleeding risk is a potential complication associated with trazodone, although the risk is lower than with other antidepressants. [24]"}
{"id": "article-30555_20", "title": "Trazodone -- Adverse Effects -- Boxed Warning", "content": "Antidepressants, including trazodone, increase the risk of\u00a0suicide in young adult and\u00a0pediatric patients. Closely monitoring trazodone-treated patients for suicidal ideation and\u00a0behaviors\u00a0is necessary. Closely monitor all antidepressant-treated patients for clinical worsening and the emergence of suicidal thoughts and behaviors. [25]", "contents": "Trazodone -- Adverse Effects -- Boxed Warning. Antidepressants, including trazodone, increase the risk of\u00a0suicide in young adult and\u00a0pediatric patients. Closely monitoring trazodone-treated patients for suicidal ideation and\u00a0behaviors\u00a0is necessary. Closely monitor all antidepressant-treated patients for clinical worsening and the emergence of suicidal thoughts and behaviors. [25]"}
{"id": "article-30555_21", "title": "Trazodone -- Adverse Effects -- Drug-Drug Interactions", "content": "CNS depressants: Trazodone\u00a0can increase the CNS depression induced by\u00a0alcohol and benzodiazepines and increase the risk of falls and injury. [26] CYP3A4 inhibitors: Consider dose reduction of trazodone due to increased bioavailability. Administration with clarithromycin increased\u00a0exposure, elimination half-life, and peak plasma concentration of trazodone.\u00a0Trazodone also reduces the clearance of trazodone, increasing the potential for adverse effects. [27] CYP3A4 inducers: Carbamazepine, an inducer of CYP3A4, reduces plasma concentration of trazodone. [28]", "contents": "Trazodone -- Adverse Effects -- Drug-Drug Interactions. CNS depressants: Trazodone\u00a0can increase the CNS depression induced by\u00a0alcohol and benzodiazepines and increase the risk of falls and injury. [26] CYP3A4 inhibitors: Consider dose reduction of trazodone due to increased bioavailability. Administration with clarithromycin increased\u00a0exposure, elimination half-life, and peak plasma concentration of trazodone.\u00a0Trazodone also reduces the clearance of trazodone, increasing the potential for adverse effects. [27] CYP3A4 inducers: Carbamazepine, an inducer of CYP3A4, reduces plasma concentration of trazodone. [28]"}
{"id": "article-30555_22", "title": "Trazodone -- Contraindications", "content": "Trazodone therapy requires careful consideration for patients\u00a0treated\u00a0with monoamine\u00a0oxidase inhibitors\u00a0(MAOIs),\u00a0including\u00a0linezolid or intravenous methylene blue. MAO inhibitors impair serotonin metabolism, and concurrent administration increases serum levels of serotonin. Therefore,\u00a0the patient must\u00a0be MAOI-free for 14 days before initiating treatment with\u00a0trazodone to reduce the risk of serotonin syndrome. In addition, concomitant use of other serotonergic drugs, such as\u00a0triptans, TCA, or fentanyl, will also increase serotonin levels. Trazodone use requires caution in patients with compromised liver function and renal function. [29]", "contents": "Trazodone -- Contraindications. Trazodone therapy requires careful consideration for patients\u00a0treated\u00a0with monoamine\u00a0oxidase inhibitors\u00a0(MAOIs),\u00a0including\u00a0linezolid or intravenous methylene blue. MAO inhibitors impair serotonin metabolism, and concurrent administration increases serum levels of serotonin. Therefore,\u00a0the patient must\u00a0be MAOI-free for 14 days before initiating treatment with\u00a0trazodone to reduce the risk of serotonin syndrome. In addition, concomitant use of other serotonergic drugs, such as\u00a0triptans, TCA, or fentanyl, will also increase serotonin levels. Trazodone use requires caution in patients with compromised liver function and renal function. [29]"}
{"id": "article-30555_23", "title": "Trazodone -- Monitoring", "content": "Baseline liver functions require monitoring before\u00a0and periodically during therapy in patients\u00a0starting on trazodone. Patients receiving trazodone should also be monitored for suicidal ideation, especially at the beginning of the treatment or following a dose increase.\u00a0Clinicians should\u00a0also monitor for signs or symptoms of serotonin syndrome.\u00a0In addition, concomitant administration of CYP 3A4\u00a0inhibitors\u00a0can lead to increased serum trazodone levels,\u00a0increasing\u00a0the risk of serotonin syndrome and cardiovascular adverse effects. [30]", "contents": "Trazodone -- Monitoring. Baseline liver functions require monitoring before\u00a0and periodically during therapy in patients\u00a0starting on trazodone. Patients receiving trazodone should also be monitored for suicidal ideation, especially at the beginning of the treatment or following a dose increase.\u00a0Clinicians should\u00a0also monitor for signs or symptoms of serotonin syndrome.\u00a0In addition, concomitant administration of CYP 3A4\u00a0inhibitors\u00a0can lead to increased serum trazodone levels,\u00a0increasing\u00a0the risk of serotonin syndrome and cardiovascular adverse effects. [30]"}
{"id": "article-30555_24", "title": "Trazodone -- Monitoring", "content": "Clinicians\u00a0should assess the response to trazodone therapy and consider augmenting or switching antidepressants if an inadequate response occurs.\u00a0For patients on digoxin therapy, therapeutic drug monitoring is recommended. [31] Concomitant administration of trazodone with warfarin requires monitoring the patient's PT/INR, possibly because of\u00a0protein or substrate binding competition between two agents. [32]", "contents": "Trazodone -- Monitoring. Clinicians\u00a0should assess the response to trazodone therapy and consider augmenting or switching antidepressants if an inadequate response occurs.\u00a0For patients on digoxin therapy, therapeutic drug monitoring is recommended. [31] Concomitant administration of trazodone with warfarin requires monitoring the patient's PT/INR, possibly because of\u00a0protein or substrate binding competition between two agents. [32]"}
{"id": "article-30555_25", "title": "Trazodone -- Toxicity", "content": "Due to trazodone's hepatic and renal metabolism, special care is necessary for patients with severe hepatic and renal impairment. Serotonin syndrome, while rare, is potentially life-threatening, presenting as a triad of mental status alteration, neuromuscular abnormality,\u00a0and\u00a0autonomic instability.\u00a0Initial clinical suspicion\u00a0varies\u00a0from presenting tremor, clonus, or akathisia. The first steps to address this condition should be discontinuing serotonergic agents, hydration, and controlling\u00a0agitation with anxiolytics. The risk is higher with certain antidepressants, antibiotics, migraine medications, antiemetics, and analgesics. Idiopathic drug-induced\u00a0liver\u00a0injury may result from trazodone administration. The timeframe typically is\u00a03 months, but reported cases require liver transplantation. [33]", "contents": "Trazodone -- Toxicity. Due to trazodone's hepatic and renal metabolism, special care is necessary for patients with severe hepatic and renal impairment. Serotonin syndrome, while rare, is potentially life-threatening, presenting as a triad of mental status alteration, neuromuscular abnormality,\u00a0and\u00a0autonomic instability.\u00a0Initial clinical suspicion\u00a0varies\u00a0from presenting tremor, clonus, or akathisia. The first steps to address this condition should be discontinuing serotonergic agents, hydration, and controlling\u00a0agitation with anxiolytics. The risk is higher with certain antidepressants, antibiotics, migraine medications, antiemetics, and analgesics. Idiopathic drug-induced\u00a0liver\u00a0injury may result from trazodone administration. The timeframe typically is\u00a03 months, but reported cases require liver transplantation. [33]"}
{"id": "article-30555_26", "title": "Trazodone -- Toxicity", "content": "Trazodone overdose can precipitate arrhythmias, respiratory arrest, coma, and priapism. A fatal\u00a0overdose has been reported after ingesting 6.45 g\u00a0of trazodone. Cerebral edema, seizures, and hyponatremia were the presenting clinical features. [34] Treatment is usually symptomatic and supportive in the case of hypotension and excessive sedation. If priapism occurs, it requires urgent urologist interventuon. Intracavernosal injection (phenylephrine injection) is indicated in patients with ischemic priapism. Monitoring\u00a0serum sodium levels and correction is necessary. [34] The medical team should call the local poison center for up-to-date guidance on trazodone overdose. [35]", "contents": "Trazodone -- Toxicity. Trazodone overdose can precipitate arrhythmias, respiratory arrest, coma, and priapism. A fatal\u00a0overdose has been reported after ingesting 6.45 g\u00a0of trazodone. Cerebral edema, seizures, and hyponatremia were the presenting clinical features. [34] Treatment is usually symptomatic and supportive in the case of hypotension and excessive sedation. If priapism occurs, it requires urgent urologist interventuon. Intracavernosal injection (phenylephrine injection) is indicated in patients with ischemic priapism. Monitoring\u00a0serum sodium levels and correction is necessary. [34] The medical team should call the local poison center for up-to-date guidance on trazodone overdose. [35]"}
{"id": "article-30555_27", "title": "Trazodone -- Enhancing Healthcare Team Outcomes", "content": "Clear communication and instruction are necessary to administer medications to patients appropriately. In addition to clinicians being able to communicate with each other, they must feel comfortable being involved in the treatment process. Psychiatrists usually prescribe trazodone for depression and insomnia. The patient usually follows up with their primary care clinician. Pharmacists should check for\u00a0drug interactions and alert the prescriber.\u00a0Specialty nurses\u00a0should educate the patients on the importance of adherence and\u00a0the drug's adverse effects.\u00a0Clinicians exhibiting appropriate empathy for patients are necessary for patients to disclose their needs to providers. [36] An interprofessional healthcare team incorporating clinicians, including clinical psychologists and pharmacists, will lead to optimal patient care with minimal adverse events when prescribing trazodone. All team members\u00a0must utilize open communication channels with\u00a0other clinical staff and be empowered to make therapeutic decisions and suggestions when they note changes in patient conditions.", "contents": "Trazodone -- Enhancing Healthcare Team Outcomes. Clear communication and instruction are necessary to administer medications to patients appropriately. In addition to clinicians being able to communicate with each other, they must feel comfortable being involved in the treatment process. Psychiatrists usually prescribe trazodone for depression and insomnia. The patient usually follows up with their primary care clinician. Pharmacists should check for\u00a0drug interactions and alert the prescriber.\u00a0Specialty nurses\u00a0should educate the patients on the importance of adherence and\u00a0the drug's adverse effects.\u00a0Clinicians exhibiting appropriate empathy for patients are necessary for patients to disclose their needs to providers. [36] An interprofessional healthcare team incorporating clinicians, including clinical psychologists and pharmacists, will lead to optimal patient care with minimal adverse events when prescribing trazodone. All team members\u00a0must utilize open communication channels with\u00a0other clinical staff and be empowered to make therapeutic decisions and suggestions when they note changes in patient conditions."}
{"id": "article-30555_28", "title": "Trazodone -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Trazodone -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}